Last reviewed · How we verify
mRNA — Competitive Intelligence Brief
marketed
mRNA therapeutic
Oncology, Immunology, Infectious Disease, Genetic Disorders
Biologic
Live · refreshed every 30 min
Target snapshot
mRNA (mRNA) — University Hospital Tuebingen. mRNA-based therapeutics deliver genetic instructions to cells to produce therapeutic proteins or trigger immune responses.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| mRNA TARGET | mRNA | University Hospital Tuebingen | marketed | mRNA therapeutic | ||
| mRNA-1083 | mRNA-1083 | ModernaTX, Inc. | phase 3 | mRNA therapeutic | myostatin |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (mRNA therapeutic class)
- ModernaTX, Inc. · 1 drug in this class
- University Hospital Tuebingen · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- mRNA CI watch — RSS
- mRNA CI watch — Atom
- mRNA CI watch — JSON
- mRNA alone — RSS
- Whole mRNA therapeutic class — RSS
Cite this brief
Drug Landscape (2026). mRNA — Competitive Intelligence Brief. https://druglandscape.com/ci/mrna. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab